In The News:
Oncobiologics Reports Second Quarter Financial Results For Fiscal 2018more >
Oncobiologics Announces $15 Million Private Placement Offeringmore >
Oncobiologics Reports First Quarter Fiscal Year 2018 Resultsmore >
Oncobiologics Receives Positive Nasdaq Listing Determinationmore >
Oncobiologics Announces Term Extension Of Series A Warrantsmore >
Oncobiologics Announces Closing Of Strategic Partnership Deal With GMS Tenshi Holdingsmore >
Oncobiologics announces strategic partnership with GMS Tenshi Holdings Pte. Limitedmore >
Oncobiologics: The most interesting biotech at JPM17?more >
Understanding Biosimilars: Despite how far we have come, there is still ample room to growmore >
How To Prepare Your Biosimilar Company For Interchangeabilitymore >
Interchangeable would be game changer for Humira competitionmore >

What We Do

Oncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Our strategy is to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company.

We have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our BioSymphony™ Platform. Oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mAb biosimilars and was designed to provide significant pricing flexibility.

We leverage the BioSymphony platform capabilities to advance our own portfolio and to offer contract development and manufacturing services to development stage biologics companies. This dual utilization allows us to deliver low cost programs internally and for our CDMO partners.....more >

Our Pipeline

Oncobiologics is currently developing a portfolio of commercially attractive mAb biosimilars.  The company’s most advanced assets, ONS-3010 (a biosimilar of Humira®) and ONS-1045 (a biosimilar of Avastin®) have both successfully completed Phase I trials. 

view full size >

CDMO Services

Oncobiologics utilizes our BioSymphony platform to provide contract development and manufacturing services to development stage biotech and biopharmaceutical partners from our 66,000 sq. ft. biologics development and manufacturing facility in Cranbury, New Jersey.

Our seasoned team of industry specialists offers partners immediate access to best-in-class infrastructure, equipment and expertise across scientific, manufacturing, regulatory and clinical functions.... more >

Company Highlights

  • ONS-3010 (Humira® biosimilar) and ONS-1045 (Avastin® biosimilar) in preparations for Phase 3 Clinical study (pending funding).
  • Active pipeline of biosimilars candidates.
  • BioSymphony™: A unique approach to biologics development and commercialization, synthesizing development, manufacturing, regulatory and program management expertise with best-in-class global clinical development and commercial partners.
  • Shared platform ensures highest quality and low-cost for internal and contract programs.
  • Rigorous engagement of orthogonal analytics to demonstrate high biosimilarityof complex mAbs.
  • An integrated development and manufacturing engine capable of generating two INDs per year.
  • Led by a team of leading scientists and engineers from the world’s top biopharmaceutical companies working in the agile, unencumbered environment of a start-up.
  • 66,000 sq. ft. facility in Cranbury, NJ and expanding.

Join Oncobiologics

Oncobiologics is a dynamic, inspiring workplace where we seek best-in-class candidates to join our existing team of renowned specialists. To learn more about opportunities with our team, please visit our careers page... more >